Depression News and Research

Latest Depression News and Research

Repligen granted Notice of Allowance covering use of uridine for treatment of bipolar disorder

Repligen Corporation announced today that the United States Patent and Trademark Office has granted a Notice of Allowance of a patent covering the use of uridine in the treatment of patients with bipolar disorder. The patent, which upon issue will remain in force until 2025 prior to any patent term extensions, covers the use of an effective dose of a uridine composition to improve one or more of the symptoms of bipolar disorder including depression, mania, mixed episodes, hypomania and anxiety.

30 Apr 2010

Low vitamin D levels may be associated with physical disability, cognitive impairment in MS patients

Low vitamin D levels may be associated with more advanced physical disability and cognitive impairment in persons with multiple sclerosis, studies conducted by neurologists at the University at Buffalo have shown.

30 Apr 2010

Investment report on Somaxon Pharmaceuticals from MicroStockProfit.com

MicroStockProfit.com announces an investment report featuring Somaxon Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

29 Apr 2010

Labopharm, Gruppo Angelini sign agreement to commercialize OLEPTRO in the U.S.

Labopharm Inc. and Gruppo Angelini today announced they have entered into an agreement to establish a joint venture in the United States for the commercialization of OLEPTRO, a novel once-daily formulation of the antidepressant trazodone approved by the U.S. Food and Drug Administration on February 3, 2010.

29 Apr 2010

22% of Canadians have contemplated or attempted suicide

On the eve of Children's Mental Health Week (May 2 to 8), Kinark Child and Family Services, a not-for-profit child and youth mental health organization in Ontario that provides expert help to children, youth and their families, released the results of a nation-wide poll that found that one in five Canadians has contemplated or attempted suicide. The online survey was conducted between April 12 and 14, 2010 with a nationally representative sample of 1,000 adults. The results are accurate to within +/- 3.1 percent at the 95% confidence level.

29 Apr 2010

Panel finds insufficient evidence to support preventive measures for cognitive decline, Alzheimer's disease

Many preventive measures for cognitive decline and for preventing Alzheimer's disease-mental stimulation, exercise, and a variety of dietary supplements-have been studied over the years. However, an independent panel convened this week by the National Institutes of Health determined that the value of these strategies for delaying the onset and/or reducing the severity of decline or disease hasn't been demonstrated in rigorous studies.

29 Apr 2010

Researchers examine how diagnosis of Fibromyalgia can affect marriages

Fibromyalgia is a condition that causes chronic, widespread pain throughout the body. In a new study, University of Missouri researchers are examining how the diagnosis of Fibromyalgia can affect marriages. Initial findings reveal that diagnosed spouses have considerably higher levels of depressive symptoms and pain and report more marital instability and anger than their spouses.

29 Apr 2010

Neurocrine Biosciences reports net loss of $8.6M in first quarter 2010

Neurocrine Biosciences, Inc. today announced its financial results for the quarter ended March 31, 2010. For the first quarter of 2010, the Company reported a net loss of $8.6 million, or $0.19 per share compared with a net loss of $19.7 million, or $0.51 per share, for the same period in 2009.

29 Apr 2010

Laughter increases production of antibodies and activates body's protective cells

Laughter is a highly complex process. Joyous or mirthful laughter is considered a positive stress (eustress) that involves complicated brain activities leading to a positive effect on health. Norman Cousins first suggested the idea that humor and the associated laughter can benefit a person's health in the 1970s. His ground-breaking work, as a layperson diagnosed with an autoimmune disease, documented his use of laughter in treating himself—with medical approval and oversight—into remission.

27 Apr 2010

Slitrk5 gene linked to development of OCD-like behaviors

Researchers at the Ansary Stem Cell Institute and the Department of Psychiatry at Weill Cornell Medical College discovered that mice missing a single gene developed repetitive obsessive-compulsive-like behaviors. The genetically altered mice, which behaved much like people with a certain type of obsessive-compulsive disorder (OCD), could help scientists design new therapies for this debilitating condition.

27 Apr 2010

RENCI project to build easy-to-use tool to help doctors determine best treatment options for patients

Gersing is the mastermind behind MindLinc, a tool for managing, evaluating and improving behavioral health treatment used at Duke and in medical clinics across the U.S. MindLinc includes anonymous emergency medical record data accumulated from psychiatric patients over 20 years. As with any large data set, quickly analyzing data and translating the analysis into better patient care poses many challenges.

27 Apr 2010

New discovery links Slitrk5 gene to development of OCD-like behaviors

27 Apr 2010

Evotec to receive EUR 1.5M from German BMBF for advancing H3 receptor antagonist programme

Evotec AG today announced that it will receive funding of up to EUR 1.5 million from the German Federal Ministry of Education and Research (BMBF) to advance its H3 receptor antagonist programme into the clinic.

27 Apr 2010

Researchers suggest association between mood and chocolate

Researchers at the University of California, San Diego School of Medicine have found that women and men eat more chocolate as depressive symptoms increase, suggesting an association between mood and chocolate.

27 Apr 2010

Military trauma transition units breed culture of drug abuse, depression

The New York Times reports on a Warrior Transition Battalion unit in Colorado used by the military to transition injured veterans back into the military or their home lives. "Created in the wake of the scandal in 2007 over serious shortcomings at Walter Reed Army Medical Center, Warrior Transition Units were intended to be sheltering way stations where injured soldiers could recuperate and return to duty or gently process out of the Army.

27 Apr 2010

Court of Appeals denies McNeil Pediatrics' CONCERTA patent appeal

The Court of Appeals for the Federal Circuit has denied an appeal by McNeil Pediatrics, a division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., to overturn a 2009 decision by the U.S. District Court of Delaware that the patent for CONCERTA (methylphenidate HCl) Extended-Release Tablets CII is invalid and not infringed by Andrx Corporation.

27 Apr 2010

Chocolate and depression?

The ‘chocoholics’ of the world may also be the most depressed people around. A recent study found that those who were suffering from depression ate an average of 8.4 servings of chocolate a month, compared to just 5.4 servings eaten by those who were not depressed. And the people who suffered from major depression ate 11.8 servings per month.

27 Apr 2010

Popular antidepressants may have beneficial side effects for cardiovascular health: Study

A class of antidepressants known as selective serotonin reuptake inhibitors may provide a boost to cardiovascular health by affecting the way platelets, small cells in the blood involved in clotting, clump together, say researchers at the Loyola University Medical Center in Maywood, Ill.

26 Apr 2010

Aton Pharma acquires the U.S. marketing rights to LODOSYN tablets from BMS

Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced that it has acquired the U.S. marketing rights to LODOSYN (carbidopa) tablets from Bristol-Myers Squibb Company.

26 Apr 2010

Covidien launches EXALGO Extended-Release Tablets in the US

Covidien, a leading global provider of healthcare products, today introduced EXALGO™ (hydromorphone HCI) Extended-Release Tablets, (CII), the only extended-release hydromorphone treatment available in the United States. This proven therapy, combined with an innovative delivery system, provides opioid-tolerant patients suffering from moderate-to-severe chronic pain relief for 24 hours per dose.

26 Apr 2010